Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week. It’s getting quieter as more people head to the beach, but some big partnerships and licensing deals have been signed and some interesting research news has been published.
- Novartis licenses eczema monoclonal antibody candidate from German Morphosys and Belgian Galapagos in deal worth up to €945M.
- Swedish rare disease company Sobi signed a €387 deal for rights to Novimmune’s antibody-based therapy for rare blood disease primary haemophagocytic lymphohistiocytosis.
- UK-biotech F-star’s lead drug candidate reached a clinical Phase I milestone in the company’s immuno-oncology collaboration with pharma giant Merck KGaA.
- Swiss scientists based in Lausanne have used synthetic biology to develop a new type of nanotube biosensor with improved sensing abilities for use in body fluids such as blood and urine, or for implantation purposes.
- BrainStorm Cell Therapeutics receives European patent for its amyotrophic lateral sclerosis treatment.
- The European Medicines Agency has endorsed a UK-US project to use an imaging biomarker to help select Parkinson’s disease patients most likely to benefit from clinical trials.
- French cancer nanotechnology company Nanobiotix have secured a loan from the European Investment Bank, which will give them access to funds of up to €40M over 5 years to develop their pipeline.
- Italian company Doulix has launched a new DNA assembly tool to help budding synthetic biologists design new genetic constructs.
- Jennewein Biotechnologie, a German company that produces rare functional sugars such as human milk oligosaccharides, has received €15M new financing from the European Investment Bank.
- Spanish & Portuguese researchers showed exposure to nanoplastics can damage DNA and cell membranes of the most common species of mussels eaten by humans.
- UK researchers have engineered a strain of rice that can withstand drought like conditions by conserving water.
Images via Shutterstock
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.